What’s new

• Orchid signs licensing and supply agreement with Russia's Pharmasyntez JSC for Exblifep
• Pharmasyntez gets exclusive rights to register and distribute in Russia; Orchid supplies finished dosage form
• Deal subject to Russian health ministry approval; potential $178M revenue over first decade

Why it matters

This is the first out-licensing deal for Exblifep, reducing execution uncertainty after telegraphed discussions. However, revenue depends on Russian regulatory approval and geopolitical stability. For a mid-cap pharma with a market cap of ₹4,886 crore, the $178M opportunity is material but long-gestation.

What we’re watching

• Timeline for Russian regulatory approval
• Further out-licensing deals in other regions
• Exblifep sales in already-approved US and EU markets

The full read

Orchid Pharma signed a licensing and supply agreement with Russia's Pharmasyntez JSC to commercialize its novel antibiotic Exblifep in the country. The deal covers exclusive rights for complicated urinary tract infections and hospital-acquired pneumonia. Revenue, though, is years away — it's contingent on Russian health ministry approval and market uptake. Still, this is the first concrete out-licensing deal for Exblifep, following earlier telegraphed discussions and a revised lifetime sales target of $2 billion. Orchid estimates the partnership could generate $178 million over the first decade from hospital procurement. That's a material opportunity for a mid-cap pharma with a market cap of ₹4,886 crore. The US and EU approvals are already in hand. The real bet: whether Pharmasyntez can navigate Russian regulatory and geopolitical hurdles to turn that $178 million into actual revenue. It won't be quick.

Primary source: BSE · NSE

What’s new

• NCLT Chennai approved the merger of Dhanuka Laboratories into Orchid Pharma.
• The scheme, first announced in March, transfers all assets and liabilities on a going-concern basis.
• The court's order copy is awaited, which will detail the final terms.

Why it matters

Court approval turns an announced plan into an executable deal. For Orchid, a small-cap pharma firm, folding Dhanuka Labs in removes the last regulatory hurdle to consolidating under the Dhanuka Group umbrella. The exact financial impact isn't yet public, but the path is clear.

What we’re watching

• The awaited NCLT order copy, which will detail any conditions attached to the sanction.
• The timeline for integration and any asset/liability specifics.
• How the combined entity's scale affects its competitive position.

The full read

The NCLT Chennai bench approved the merger of Dhanuka Laboratories into Orchid Pharma on Friday. This is the final regulatory hurdle cleared. The scheme, first announced in March, transfers all assets and liabilities on a going-concern basis. It allows the small-cap pharma firm to consolidate under the Dhanuka Group. The order copy is awaited and will set the precise terms. The deal's strategic logic is operational consolidation. But the financial scale of the integration remains undisclosed. The approval shifts the story from announcement to implementation. Not yet complete, though. Integration is the real test.

Primary source: BSE · NSE

What’s new

• Orchid expects to sign an out-licensing deal for Enmetazobactam this quarter.
• The company is building fill-finish capabilities to enter the US sterile cephalosporin market.
• The 7ACA fermentation project remains on track for commissioning in Q1 CY27.

Why it matters

The sterile cephalosporin push is a new capital commitment into a large, defined market. For a company of Orchid's size, it's a significant bet on execution. The Enmetazobactam deal, now expected this quarter, is the more immediate catalyst after repeated timeline slippages.

What we’re watching

• Whether the Enmetazobactam out-licensing deal closes this quarter.
• Capital costs and timeline for the sterile fill-finish facility.
• Progress on the Dhanuka Laboratories merger, pending a court order.

The full read

Orchid Pharma is adding a second act. Alongside the long-running Enmetazobactam story, management said it is building sterile fill-finish capabilities to enter the US cephalosporin market. The target: 5-6 products in a $1.2 billion opportunity. This is new capital commitment. The first Enmetazobactam out-licensing deal, covering the US, Japan, and Latin America, is now due this quarter. Management repeated the $1-2 billion lifetime sales guidance but the timeline has been the sticking point. A signed deal would validate the asset. Separately, the 7ACA fermentation plant is on track for commissioning in Q1 CY27 and the Dhanuka Laboratories merger awaits a court order. The Enmetazobactam deal is the near-term test.

Primary source: BSE · NSE

What’s new

• Lifetime revenue guidance for Enmetazobactam jumped from $200-250 million to $1-2 billion.
• Peak sales are now anticipated in the fourth or fifth year post-launch.
• No binding out-licensing agreements were signed, despite management's prior hopes.

Why it matters

The massive revision to lifetime sales targets suggests management has gained conviction in the drug's market potential. The lack of a concrete out-licensing deal leaves a gap between ambition and current commercial reality. The next test is a signed contract to validate these upgraded projections.

What we’re watching

• Updates on out-licensing discussions in the US, Japan, and Latin America.
• Commissioning of the 7-ACA fermentation project in Q1 FY27.
• Progress on the pending court order for the Dhanuka Labs merger.

The full read

Orchid Pharma has aggressively revised its outlook for its flagship antibiotic, Enmetazobactam. Management now targets lifetime revenue of $1-2 billion, a massive jump from the prior $200-250 million estimate. This upgrade comes with a longer runway, as peak sales are now pushed to the fourth or fifth year of the launch cycle.

But the company failed to deliver on its hope of announcing a binding out-licensing deal during the call. Discussions remain active across the US, Japan, and Latin America. The timeline for a signature is uncertain.

Elsewhere, the 7-ACA fermentation project remains on schedule for a Q1 2027 commissioning, and the Dhanuka Labs merger is still awaiting a court order. Management is aiming for 10-15% growth in the base business with 12% EBITDA margins by FY27. The strategy is clear. The valuation of these long-term targets now hinges on securing the first major partnership.

Primary source: BSE · NSE

What’s new

• Standalone annual net profit fell to ₹45.2 crore from ₹106.5 crore in the prior year.
• Q4 standalone profit reached ₹30.6 crore, recovering from a Q3 loss.
• Consolidated results carry a qualified audit opinion regarding unaudited US subsidiaries.

Why it matters

The earnings erosion was expected, but the qualified audit opinion on consolidated results introduces a layer of uncertainty regarding the company's US operations. Investors should look past the Q4 recovery to the structural decline in annual profitability.

What we’re watching

• Any clarification on the status of the US subsidiaries.
• Management commentary on the sustainability of the Q4 profit rebound.
• Resolution of the audit qualification in future filings.

The full read

Orchid Pharma closed the fiscal year with a standalone net profit of ₹45.2 crore. This is a sharp decline from the ₹106.5 crore recorded in the previous year. While the company managed a Q4 standalone profit of ₹30.6 crore—recovering from a loss in the preceding quarter—the broader annual trend remains weak. Consolidated financial results carry a qualified audit opinion. This qualification specifically cites the lack of audits for the company's US subsidiaries. These figures align with prior guidance and quarterly disclosures, offering no surprises for investors. The appointment of an internal auditor was also confirmed as a standard procedural step. The primary issue remains the quality of the consolidated reporting, which is currently hampered by the unaudited status of international units. It is a messy finish to the year.

Primary source: BSE · NSE

What’s new

• FY26 standalone net profit fell 57% to ₹45.2 cr from ₹106.5 cr the prior year.
• Consolidated net profit plunged 79% to ₹20.5 cr, with auditors issuing a qualified opinion.
• Q4 standalone profit rose to ₹30.6 cr, a sequential recovery but still modest.

Why it matters

The earnings collapse is now audited and confirmed. The qualified opinion on consolidated accounts over three unaudited US subsidiaries adds a governance headache on top of the margin compression. This was largely anticipated after Q3 and a credit rating downgrade, but the final numbers remove any ambiguity about the scale of the deterioration.

What we’re watching

• Management's explanation for the 79% consolidated profit drop beyond 'higher costs'.
• Any corrective action or audits planned for the US subsidiaries flagged by the auditor.
• Whether the Q4 standalone sequential recovery can be sustained into FY27.

The full read

Orchid Pharma's audited FY26 results are in, and they're bad. Standalone net profit fell 57% to ₹45.2 crore from ₹106.5 crore the prior year. The consolidated picture is worse: a 79% collapse to ₹20.5 crore. The fourth quarter did show a sequential bounce to ₹30.6 crore in standalone profit, but that single quarter accounts for over two-thirds of the year's total earnings. The consolidated accounts come with a qualified auditor opinion, a red flag over three unaudited US subsidiaries the auditor says have negligible operations. These results were widely anticipated after Q3 showed the same slide and a credit downgrade followed. This filing removes any doubt about the scale of the damage. The open question is whether the Q4 uptick is a bottom or just the low base of a terrible year.

Primary source: BSE · NSE

What’s new

• Orchid Pharma's FY26 standalone net profit fell 57.5% to ₹45.2 crore from ₹106.5 crore a year earlier.
• Consolidated net profit dropped 79.4% to ₹20.5 crore, indicating severe margin compression.
• Auditors issued a qualified opinion on consolidated results, citing unaudited financials from three US subsidiaries.

Why it matters

The profit decline is sharp, but the auditor's qualified opinion is the more serious issue. It means the consolidated numbers cannot be fully trusted because the US subsidiaries' finances are unverified. This is a recurring governance problem, not a one-off.

What we’re watching

• Whether the US subsidiary audit issue gets resolved before the next filing.
• The impact of prior credit rating downgrades on future funding costs.
• The path back to profitability after the full-year EPS collapse.

The full read

Orchid Pharma's FY26 numbers tell a story of collapsing profitability. Standalone net profit fell 57.5% to ₹45.2 crore from ₹106.5 crore, and the consolidated picture is worse: profit there dropped 79.4% to ₹20.5 crore. Full-year standalone EPS crumbled to ₹8.91 from ₹20.99. The Q4 standalone profit of ₹30.6 crore offered a modest rebound, but it came with an exceptional item reversal of about ₹0.5 crore and was not enough to salvage the year. The deeper concern is the auditor's qualified opinion on the consolidated accounts. The issue is three US subsidiaries whose financials remain unaudited, a recurring governance gap. This is the same company that saw a credit rating downgrade. The operational headwinds are now joined by a trust deficit in the numbers themselves.

Primary source: BSE · NSE